Bone mineral density in feline mucopolysaccharidosis VI measured using dual-energy X-ray absorptiometry.
Dual-energy X-ray absorptiometry (DXA) was used to determine the in vivo bone mineral density (BMD) and bone mineral content (BMC) of lumbar vertebrae in six cats affected with the inherited lysosomal storage disease mucopolysaccharidosis VI (MPS VI). DXA was also performed on MPS cats that had a bone marrow transplant (BMT) and total body irradiation (TBI) (MPS + BMT; n = 7), normal cats that had a bone marrow transplant, and TBI (control + BMT; n = 8) and normal cats (control; n = 14). Following euthanasia, one of the lumbar vertebrae that had been scanned (L5) was harvested and bone volume (BV/TV%) was determined by histomorphometry. The in vivo BMD and BMD measurements were compared with the BV/TV%. There was a greater BMD and BMC in the MPS + BMT cats compared with the MPS cats but the difference was not statistically significant. However, there was a greater BV/TV% in the MPS + BMT cats compared with the MPS cats and the difference was significant (P = 0.0152). Correlation between the noninvasive in vivo DXA measurements of BMD and BMC and the BV/TV% was significant (r2 = 0.767, P < 0.0001; r2 = 0.504, P < 0.0001). Noninvasive in vivo DXA was a rapid and precise method for measuring the lumbar BMD and BMC in cats and it correlated well with histomorphometric determination of bone mass. Further, the response of inherited storage diseases such as MPS VI to therapy, such as BMT, could be monitored in a longitudinal fashion using DXA.
Turner
A S
AS
Department of Clinical Sciences, Colorado State University, Ft. Collins 80523, USA.
Norrdin
R W
RW
Gaarde
S
S
Connally
H E
HE
Thrall
M A
MA
D015502:Absorptiometry, Photon / Q000295:instrumentation; D000818:Animals; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000473:pathology; D016026:Bone Marrow Transplantation; D002415:Cats; D003430:Cross-Sectional Studies; D005069:Evaluation Studies as Topic; D008159:Lumbar Vertebrae / Q000473:pathology; D009087:Mucopolysaccharidosis VI / Q000378:metabolism / Q000473:pathology* / Q000628:therapy